PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

Bannon’s War Room | Episode 2280 | Evening Edition | Recorded November 4, 2022 | Video: 49 Minutes

Show Me

The Queen Of Blue Anon Conspiracies Is At It Again | Hillary Clinton Claims GOP Plots to “Literally Steal” 2024 Election | American Center For Law and Justice

Show Me

NTD News Today Full Broadcast (Nov. 4, 2022) | Video: 53 Minutes 50 Seconds

Show Me

Bannon’s War Room | Episode 2279 | Morning Edition Hour 2 | Recorded November 3, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Bannon’s War Room | Episode 2278 | Morning Edition Hour 1 | Recorded November 3, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Dr. McCullough with Kevin Hogan: Medical Boards Pandemic Retaliation | Dr. Peter McCullough | Video: 4 Minutes

Show Me

Nightly News Rebroadcast | November 3, 2022 | Video: 25 Minutes 9 Seconds

Show Me

Bannon’s War Room | Episode 2277 | Evening Edition | Recorded November 2, 2022 | Video: 48 Minutes 59 Seconds

Show Me

NTD News Today Full Broadcast | November 3, 2022 | Video: 53 Minutes 9 Seconds

Show Me

Sometimes Only Satire Can Show Us Where We Are | “DHS Announces They Will Suppress As Much Speech As It Takes To Preserve Democracy” | Babylon Bee

Show Me

Never Forget | As Expected, For The Left, ‘Treason’ Against America Is ‘Patriotism’ To Globalists | Joy Reid Calls Gen. Mark Milley ‘Heroic,’ ‘Patriot’ | The Daily Caller

Show Me

Bannon’s War Room | Episode 2276 | Morning Edition Hour 2 | Recorded November 3, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Bannon’s War Room | Episode 2275 | Morning Edition Hour 1 | Recorded November 3, 2022 | Video: 55 Minutes 53 Seconds

Show Me

Lee Zeldin’s Ad Shows The Real Consequences Of Rising Crime Under Democrat Governance

Show Me

Dr. Victor Frankenstein’s Failure | Dr. Peter A. McCullough and John Leake

Show Me

Nightly News Rebroadcast | November 2, 2022 | Video: 25 Minutes 10 Seconds

Show Me

Bannon’s War Room | Episode 2274 | Evening Edition | Recorded November 2, 2022 | Video: 48 Minutes 58 Seconds

Show Me

NY Man Released Without Bail After Savagely Beating Ex-Wife Immediately Kills Her Upon Release | National File

Show Me

Arizona State Rep. Mark Finchem Credits Elon Musk for Restored Twitter Account | The Epoch Times

Show Me

CNBC’s Jim Cramer Calls for State-Run Propaganda to Spread COVID Agenda – Leaving his Co-hosts in Awkward Silence | The Gateway Pundit

Show Me

COVID Is on the Ballot Next Week and Running as a Democrat | PJ Media

Show Me

U.S. Capitol Police had live video feed at Pelosi home but didn’t notice break-in: Sources | Just The News

Show Me

Key Hasidic groups back Lee Zeldin as Kathy Hochul continues push for Orthodox support | The New York Post

Show Me

Jewish Community Center to Host Drag Queen Story Hour As Part Of ‘Family Fun’ Day | The Daily Caller

Show Me

Bannon’s War Room | Episode 2273 | Morning Edition Hour 2 | Recorded November 2, 2022 | Video: 48 Minutes 59 Seconds

Show Me

Bannon’s War Room | Episode 2272 | Morning Edition Hour 1 | Recorded November 2, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Apparent Mass Purge of Twitter Accounts | NTD | Video: 4 Minutes 30 Seconds

Show Me

Bannon’s War Room | Episode 2271 | Evening Edition | Recorded November 1, 2022 | Video: 48 Minutes 59 Seconds

Show Me

Nightly News Rebroadcast | November 1, 2022 | Video: 26 Minutes 13 Seconds

Show Me

NTD News Today Full Broadcast (Nov. 1) | Video: 53 Minutes 16 Seconds

Show Me

Bannon’s War Room | Episode 2270 | Morning Edition Hour 2 | Recorded November 1, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Bannon’s War Room | Episode 2269 | Morning Edition Hour 1 | Recorded November 1, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Nightly News Rebroadcast | October 31, 2022 | Video: 25 Minutes 56 Seconds

Show Me

Bannon’s War Room | Episode 2268 | Evening Edition | Recorded October 31, 2022 | Video: 48 Minutes 58 Seconds

Show Me

China Dismisses ‘Fabricated’ Virus Leak Theory Revived by Report | Bloomberg

Show Me

Archivists Discovered the Oldest Known Map of the Stars Under a Christian Manuscript

Show Me

Commentary: Elon Musk Is a Much-Needed Insult to the Coddled Consensus Class That Is Ruining America | Georgia Star News

Show Me

LIVE 10/31, at 10:30 AM ET: FBI Wants 66 Years to Release Seth Rich Data; Democrats Claim ‘Right Wing’ Will Steal the Elections | The Epoch Times

Show Me

Bannon’s War Room | Episode 2267 | Morning Edition Hour 2 | Recorded October 31, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Bannon’s War Room | Episode 2266 | Morning Edition Hour 1 | Recorded October 31, 2022 | Video: 48 Minutes 58 Seconds

Show Me